# Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

> **NCT03429075** · PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 59 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Psilocybin + Placebo
- **DRUG:** Psilocybin + Escitalopram

## Key facts

- **NCT ID:** NCT03429075
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2020-04-17
- **Final completion:** 2020-10-17
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03429075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03429075, "Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03429075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*